PERALDO NEIA, CATERINA
 Distribuzione geografica
Continente #
NA - Nord America 468
EU - Europa 118
AS - Asia 106
AF - Africa 6
SA - Sud America 4
OC - Oceania 3
Totale 705
Nazione #
US - Stati Uniti d'America 461
CN - Cina 57
IT - Italia 34
DE - Germania 20
VN - Vietnam 18
FR - Francia 16
KR - Corea 16
PL - Polonia 8
RU - Federazione Russa 7
CA - Canada 6
ES - Italia 6
GB - Regno Unito 5
NL - Olanda 5
ZA - Sudafrica 5
CZ - Repubblica Ceca 4
GR - Grecia 4
JP - Giappone 4
MY - Malesia 4
AU - Australia 3
CL - Cile 3
AT - Austria 2
CH - Svizzera 2
FI - Finlandia 2
ID - Indonesia 2
RO - Romania 2
BR - Brasile 1
BT - Bhutan 1
IN - India 1
MX - Messico 1
NG - Nigeria 1
TH - Thailandia 1
TR - Turchia 1
TW - Taiwan 1
UA - Ucraina 1
Totale 705
Città #
Fairfield 52
Buffalo 43
Houston 42
Santa Cruz 32
Ashburn 28
Seattle 27
Woodbridge 27
Cambridge 22
Beijing 17
Dong Ket 16
Wilmington 16
Ann Arbor 13
Shanghai 12
Dallas 9
Mountain View 8
Pisa 8
Torino 8
Warsaw 8
University Park 6
Wuhan 6
Boardman 5
Las Vegas 5
Nanjing 5
Chicago 4
Muizenberg 4
Phoenix 4
Athens 3
Büdelsdorf 3
Catania 3
Chengdu 3
Guangzhou 3
Los Angeles 3
Ottawa 3
Rochester 3
Rome 3
Tokyo 3
Clearwater 2
Easton 2
Fleming Island 2
Helsinki 2
Kuching 2
Ningbo 2
San Francisco 2
Annapolis 1
Auburn 1
Augusta 1
Barcelona 1
Barceloneta 1
Berlin 1
Bern 1
Bethesda 1
Blackpool 1
Burlington 1
Canberra 1
Cape Town 1
Cedar Crest 1
Cesena 1
Cheyenne 1
Cislago 1
Collegeville 1
Columbus 1
Crugers 1
Des Moines 1
Farmington 1
Franklin 1
Freiburg 1
Gaithersburg 1
Greifswald 1
Hamilton 1
Henderson 1
Jakarta 1
Jersey City 1
Kuala Lumpur 1
La Jolla 1
Lake Forest 1
Latrobe 1
Leawood 1
Lexington 1
London 1
Maastricht 1
Madrid 1
Mainz 1
Mcallen 1
Milan 1
Monterrey 1
Mount Kisco 1
Mumbai 1
Muttenz 1
Nantes 1
Napoli 1
New Orleans 1
New York 1
Niagara-on-the-lake 1
Nürnberg 1
Orlando 1
Palo Alto 1
Pamplona 1
Portland 1
Providence 1
Provo 1
Totale 528
Nome #
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma, file e27ce429-ba01-2581-e053-d805fe0acbaa 176
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer, file e27ce426-fd7a-2581-e053-d805fe0acbaa 147
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models., file e27ce427-0f27-2581-e053-d805fe0acbaa 135
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma, file e27ce42c-d6c3-2581-e053-d805fe0acbaa 106
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation., file e27ce428-9b06-2581-e053-d805fe0acbaa 102
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation., file e27ce428-9fed-2581-e053-d805fe0acbaa 56
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT), file 1ee61ccb-4bc7-418c-9811-db7c66045a3f 7
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib, file e27ce426-c5d7-2581-e053-d805fe0acbaa 4
Antitumor activity of Src inhibitor Saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas., file e27ce426-d2da-2581-e053-d805fe0acbaa 1
Totale 734
Categoria #
all - tutte 1.124
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.124


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201990 0 0 0 0 0 0 0 13 11 16 31 19
2019/2020175 18 15 12 34 11 13 10 15 14 15 12 6
2020/2021124 7 4 11 13 10 15 10 7 7 15 6 19
2021/2022119 17 9 5 6 9 6 6 6 3 7 32 13
2022/202384 3 0 30 20 0 5 5 5 3 2 10 1
2023/202429 5 0 3 2 3 1 7 8 0 0 0 0
Totale 734